C.R. Jackson
Biotech, healthcare, value, research analyst

Near A 52-Week Low, Is Ventrus Biosciences A Good Buy?

Based in New York City, New York, Ventrus Biosciences, Inc. (VTUS), is a development stage specialty pharmaceutical company focused on late stage drugs for gastrointestinal disorders. The 40M market cap company is developing two product candidates:

  • Diltiazem cream (VEN 307), a topical treatment for the relief of pain associated with anal fissures; and
  • Phenylephrine gel (VEN 308) for the treatment of fecal incontinence associated with ileal pouch anal anastomosis.

Many investors gave up on Ventrus after the company's lead product, iferanserin (VEN 309), a new topical treatment of hemorrhoids failed a Phase 3 trial. There were high hopes that the drug would be a blockbuster for Ventrus because there are no US Food and

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details